scispace - formally typeset
F

Fazlul H. Sarkar

Researcher at Wayne State University

Publications -  626
Citations -  48133

Fazlul H. Sarkar is an academic researcher from Wayne State University. The author has contributed to research in topics: Cancer & Pancreatic cancer. The author has an hindex of 114, co-authored 625 publications receiving 44744 citations.

Papers
More filters
Journal ArticleDOI

Exosomes in Cancer Development, Metastasis and Drug Resistance: A Comprehensive Review

TL;DR: It is proposed that the successful combination of cancer treatments to tackle exosome-mediated drug resistance requires an interdisciplinary understanding of these cellular exclusion mechanisms, and how secreted biomolecules are involved in cellular cross-talk within the tumor microenvironment.
Journal ArticleDOI

Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin.

TL;DR: It is demonstrated that alpha v beta 3 antagonists may provide an effective antiangiogenic approach for the treatment of human breast cancer.
Journal ArticleDOI

Up-regulation of miR-200 and let-7 by Natural Agents Leads to the Reversal of Epithelial-to-Mesenchymal Transition in Gemcitabine-Resistant Pancreatic Cancer Cells

TL;DR: Experimental evidence is provided, for the first time, that DIM and isoflavone could function as miRNA regulators leading to the reversal of EMT phenotype, which is likely to be important for designing novel therapies for pancreatic cancer.
Journal ArticleDOI

Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling Pathway

TL;DR: Molecular evidence is provided showing that the activation of Notch signaling is mechanistically linked with chemoresistance phenotype (EMT phenotype) of PC cells, suggesting that the inactivation of notch signaling by novel strategies could be a potential targeted therapeutic approach for overcoming chemores resistance toward the prevention of tumor progression and/or treatment of metastatic PC.
Journal ArticleDOI

Multi-targeted therapy of cancer by genistein

TL;DR: Both in vivo and in vitro studies have clearly shown that genistein, one of the major soy isoflavones is a promising agent for cancer chemoprevention and further suggest that it could be an adjunct to cancer therapy by virtue of its effects on reversing radioresistance and chemoresistance.